Kathleen A. Cooney
A5010980781- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
- Genetic Associations and Epidemiology
- Genetic factors in colorectal cancer
- BRCA gene mutations in cancer
- Genetic and Clinical Aspects of Sex Determination and Chromosomal Abnormalities
- Cancer, Lipids, and Metabolism
- Epigenetics and DNA Methylation
- Human-Animal Interaction Studies
- DNA Repair Mechanisms
- Cancer Genomics and Diagnostics
- Health Systems, Economic Evaluations, Quality of Life
- Cancer-related molecular mechanisms research
- Molecular Biology Techniques and Applications
- Hormonal and reproductive studies
- Cancer-related gene regulation
- Genetic and phenotypic traits in livestock
- Platelet Disorders and Treatments
- Global Cancer Incidence and Screening
- Sexual Differentiation and Disorders
- Blood groups and transfusion
- Nutrition, Genetics, and Disease
- Animal testing and alternatives
- PARP inhibition in cancer therapy
- Bone health and treatments
Duke University
2019-2025
Duke Medical Center
2022-2025
Duke Cancer Institute
2019-2024
University of Michigan
2010-2023
Colorado State University
2022-2023
NorthShore University HealthSystem
2017-2022
Johns Hopkins University
2011-2022
The Barbara Ann Karmanos Cancer Institute
2022
Wayne State University
2022
ORCID
2021
Family history is a significant risk factor for prostate cancer, although the molecular basis this association poorly understood. Linkage studies have implicated chromosome 17q21-22 as possible location of prostate-cancer susceptibility gene.We screened more than 200 genes in region by sequencing germline DNA from 94 unrelated patients with cancer families selected linkage to candidate region. We tested family members, additional case subjects, and control subjects characterize frequency...
A whole-genome admixture scan in 1,597 African Americans identified a 3.8 Mb interval on chromosome 8q24 as significantly associated with susceptibility to prostate cancer [logarithm of odds (LOD) = 7.1]. The increased risk because inheriting ancestry is greater men diagnosed before 72 years age (P < 0.00032) and may contribute the epidemiological observation that higher for greatest younger (and attenuates older age). same region was recently through linkage analysis cancer, followed by...
Prostate cancer (CaP) is the leading among men of African descent in USA, Caribbean, and Sub-Saharan Africa (SSA). The estimated number CaP deaths SSA during 2008 was more than five times that Americans expected to double by 2030. We summarize publicly available data collected from Carcinoma (MADCaP) Consortium Caribbean Cancer (AC3) evaluate incidence mortality worldwide. are highest USA Caribbean. Tumor stage grade were SSA. report a higher proportion T1 prostate tumors countries with...
Germline testing (GT) is a central feature of prostate cancer (PCA) treatment, management, and hereditary assessment. Critical needs include optimized multigene strategies that incorporate evolving genetic data, consistency in GT indications alternate evaluation models address the rising demand for services. A multidisciplinary consensus conference included experts, stakeholders, national organization leaders was convened response to current practice challenges develop implementation...
Next-generation sequencing (NGS) has enabled genome-wide personalized oncology efforts at centers and companies with the specialty expertise infrastructure required to identify prioritize actionable variants. Such approaches are not scalable, preventing widespread adoption. Likewise, most targeted NGS fail assess key relevant genomic alteration classes. To address these challenges, we predefined catalog of solid tumor somatic genome variants (gain-of-function or loss-of-function mutations,...
Purpose To determine whether cotargeting poly (ADP-ribose) polymerase-1 plus androgen receptor is superior to inhibition in metastatic castration-resistant prostate cancer (mCRPC) and ETS fusions predict response. Patients Methods underwent site biopsy were stratified by status randomly assigned abiraterone prednisone without (arm A) or with veliparib B). Primary objectives were: confirmed prostate-specific antigen (PSA) response rate (RR) predicted Secondary safety, measurable disease RR...
Intracranial germ cell tumors are a heterogeneous group of lesions which occur in children and adults. Within the classification intracranial tumors, there variety different tumor types carry prognoses. The diagnosis an usually requires histological information, but subgroup will secrete specific markers, including alpha-fetoprotein beta-human chorionic gonadotropin, may obviate need for surgical intervention. management both adults remains unsettled. Germinomas have good prognosis, as over...
Background: Recent recognition that a predisposition to prostate cancer can be inherited has led search for specific genes associated with the disease. Through study of families three or more affected first-degree relatives, region on long arm chromosome 1 (i.e., 1q24-25) been tentatively identified as containing gene, HPC1, involved in development hereditary cancer. Confirmation this finding is needed, however, before attempts are made isolate and characterize putative HPC1 gene. Purpose:...
Prostate cancer has a strong familial component but uncovering the molecular basis for inherited susceptibility this disease been challenging. Recently, rare, recurrent mutation (G84E) in HOXB13 was reported to be associated with prostate risk. Confirmation and characterization of finding is necessary potentially translate information clinic. To examine large international sample families, we genotyped 14 other SNPs or flanking 2,443 families recruited by International Consortium Cancer...
Prostate cancer has been described as a component tumor of Lynch syndrome (LS), with tumors obtained from mutation carriers demonstrating the DNA mismatch repair deficiency phenotype. Previous studies quantifying prostate risk in LS have provided conflicting results.We examined histories probands and their first- through fourth-degree relatives for 198 independent mutation-positive families enrolled two US familial registries. Modified segregation analysis was used to calculate age-specific...
BACKGROUND The survival of men diagnosed with prostate cancer has improved over time, and the current 10‐year relative rate is 99.7%. long patients this common raises questions about risk a second primary need for continued surveillance. METHODS A population‐based cohort 441,504 who were between 1992 2010 was identified from Surveillance, Epidemiology End Results Program (SEER) data (SEER13). standardized incidence ratio (SIR) calculated as an estimate malignancy based on in general...